Good
Partially Aligned
Patient Risk:
Moderate
Summary
Most statements in the AI-generated claims are generally consistent with the provided Klonopin (clonazepam) label excerpts (indications, CNS depression/sedation, opioid/alcohol interaction warnings, and dependence/withdrawal with taper). However, several safety/dose/label-precision items are either not explicitly supported in the provided excerpts (e.g., specific dosage-by-mouth schedule language beyond general dosing direction; pregnancy/breastfeeding being individualized without the clinician-discussion wording; specific adverse reaction proportions), or not fully corroborated with the excerpted label text (e.g., urgent-care phrasing; specific descriptors like 'breathing suppression').
Category Scores
Accurate Statements
Clonazepam tablets are a benzodiazepine medicine.
Supported by general label context (benzodiazepine class references present in WARNINGS/INTERACTIONS excerpts: 'Concomitant use of benzodiazepines, including Klonopin').
Clonazepam tablets are used to treat certain seizure disorders.
Supported in INDICATIONS AND USAGE excerpt: 'Klonopin is useful... in the treatment of the Lennox-Gastaut syndrome... akinetic, and myoclonic seizures...' and 'absence seizures... may be useful.'
Clonazepam tablets are used for seizure disorders including forms of epilepsy, as directed by a clinician.
Supported on-label for seizure disorders; excerpted label provides adult seizure disorder dosing and usage (2 DOSAGE AND ADMINISTRATION) though clinician-directed phrasing itself is not explicitly quoted.
Clonazepam tablets are used to treat panic disorder (with or without fear of having more panic attacks).
Supported by INDICATIONS AND USAGE excerpt: 'Klonopin is indicated for the treatment of panic disorder, with or without agoraphobia...' (AI phrasing maps to panic-related symptoms; 'fear of having more panic attacks' is not label-quoted).
Clonazepam tablets are taken by mouth on a schedule set by the prescriber.
Partially supported: label excerpts include oral use implicitly in 'Dosage and Administration' and dosing individualized by condition/response; however 'on a schedule set by the prescriber' is not directly quoted.
Dosing of clonazepam is individualized based on the condition being treated, response to therapy, age, and other medications.
Partially supported: INDICATIONS/2 DOSAGE AND ADMINISTRATION include different starting/maximum doses by condition; provided excerpts do not explicitly mention age/other medications as dosing factors.
Clonazepam can cause sedation.
Supported by WARNINGS/5 WARNINGS excerpt: 'Since Klonopin produces CNS depression...' and by 6 ADVERSE REACTIONS excerpt describing CNS depression (drowsiness/somnolence).
Extra caution with driving or operating machinery is important until patients know how clonazepam affects them.
Supported by 5 WARNINGS excerpt: 'patients... should be cautioned against engaging in hazardous occupations...'.
Common effects of clonazepam include sleepiness or fatigue.
Supported by 6 ADVERSE REACTIONS excerpt: 'drowsiness... approximately 50%'.
Common effects of clonazepam include dizziness or trouble with coordination.
Partially supported: 6 ADVERSE REACTIONS excerpt mentions 'ataxia' (coordination-related) but does not explicitly mention 'dizziness' in the provided snippet.
Common effects of clonazepam include slowed thinking or reaction time.
Partially supported: 5 WARNINGS excerpt notes CNS depression and hazardous occupations; specific 'slowed thinking/reaction time' wording is not directly quoted.
Stopping clonazepam suddenly can cause withdrawal symptoms.
Supported by 5 WARNINGS excerpt: 'Abrupt discontinuation or rapid dosage reduction... may precipitate acute withdrawal reactions...'.
Discontinuation of clonazepam should be done only with a clinician’s guidance, usually by tapering the dose gradually.
Supported by 2 DOSAGE AND ADMINISTRATION excerpt: 'use a gradual taper to discontinue Klonopin...' and 5 WARNINGS: 'use a gradual taper...'. 'Clinician guidance' is implied but not directly quoted.
Decisions about clonazepam in pregnancy depend on individual risks and benefits.
Partially supported by 8 USE IN SPECIFIC POPULATIONS excerpt: neonatal sedation/withdrawal risk and monitoring statements; provided excerpt does not explicitly include 'individual risks and benefits' wording.
Decisions about clonazepam in breastfeeding depend on individual risks and benefits.
Partially supported by 8 USE IN SPECIFIC POPULATIONS excerpt: 'excreted in human milk... reports of sedation, poor feeding and poor weight gain...' (individual risk/benefit framing is not explicitly quoted).
Patients should discuss clonazepam use in pregnancy or breastfeeding with their clinician rather than starting, changing, or stopping on their own.
Not explicitly supported in provided excerpts (the excerpted pregnancy/breastfeeding content includes monitoring/risk notes but does not contain this counseling phrasing).
Alcohol increases sedation and impairment when used with clonazepam.
Supported by 7 DRUG INTERACTIONS excerpt: 'The CNS-depressant action... may be potentiated by... alcohol...' (AI adds 'impairment' which is consistent with CNS depression but not directly quoted).
Opioids and other sedatives increase the risk of respiratory depression when used with clonazepam.
Supported by 5 WARNINGS excerpt: 'concomitant use... with opioids may result in... respiratory depression...' and 7 DRUG INTERACTIONS excerpt: 'increases the risk of respiratory depression.'
Other medicines that affect the brain and nervous system can add to sedation when used with clonazepam.
Supported by 7 DRUG INTERACTIONS excerpt: 'The CNS-depressant action... may be potentiated by... other anticonvulsant drugs.' (AI broadly states 'other medicines that affect the brain and nervous system'; the excerpt supports potentiation of CNS depressant action but not the exact breadth).
Unsupported Statements
Clonazepam tablets are used for seizure disorders including forms of epilepsy, as directed by a clinician.
While seizure indications are supported, the excerpt does not explicitly include the 'as directed by a clinician' phrasing.
Clonazepam tablets are used to treat panic disorder (with or without fear of having more panic attacks).
Label excerpt specifies 'panic disorder, with or without agoraphobia' but does not mention 'fear of having more panic attacks' in the provided text.
Clonazepam tablets are taken by mouth on a schedule set by the prescriber.
Oral administration is consistent, but the provided excerpts do not explicitly state 'on a schedule set by the prescriber.'
Dosing of clonazepam is individualized based on the condition being treated, response to therapy, age, and other medications.
Provided excerpts clearly differentiate dosing by condition and include discontinuation/taper guidance; however the excerpt does not explicitly state age and 'other medications' as dosing factors.
Seek urgent care if severe breathing problems, extreme confusion, or signs of overdose occur while taking clonazepam.
The excerpts include severe outcomes (profound sedation/respiratory depression/coma/death) but do not provide instructions to seek 'urgent care' with this specific wording.
Mixing clonazepam with other medicines that depress the central nervous system, including alcohol or opioids, increases the risk of dangerous sedation and breathing suppression.
The label excerpts support opioid co-use risks (including respiratory depression) and alcohol potentiation of CNS depression; however 'breathing suppression' and 'dangerous sedation' phrasing is not explicitly in the provided label text.
Other medicines that affect the brain and nervous system can add to sedation when used with clonazepam.
The provided interaction excerpt supports potentiation of CNS-depressant action by alcohol/narcotics and other listed agents, but the broad statement about 'other medicines that affect the brain and nervous system' is not explicitly enumerated in the excerpt.
Patients should discuss clonazepam use in pregnancy or breastfeeding with their clinician rather than starting, changing, or stopping on their own.
Not explicitly stated in provided pregnancy/breastfeeding excerpts.
Contradictions
Important Omissions
Contraindications (history of sensitivity to benzodiazepines, significant liver disease, acute narrow angle glaucoma) were not mentioned in the AI claims.
Importance:
Moderate
Boxed warning content (e.g., class warning language) was not mentioned.
Importance:
Moderate
Specific discontinuation guidance that includes 'increased seizure frequency and status epilepticus' risks (besides withdrawal) was not mentioned.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Core high-level safety themes (opioid co-use respiratory depression, CNS depression/sedation, and dependence/withdrawal with taper) are present and largely consistent with excerpts. However, some safety instructions are not explicitly label-supported (e.g., urgent-care phrasing), and key label elements like contraindications and boxed-warning content were omitted.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Several claims are not directly supported by the provided label excerpts (specific phrasing such as panic definition details, urgent-care instructions, broad 'other medicines' language, and pregnancy/breastfeeding counseling wording). Contraindications and boxed warning language are omitted.
Suggested Improvement
Restrict wording to language explicitly present in the supplied excerpts (e.g., 'panic disorder... with or without agoraphobia'; avoid 'fear of more panic attacks' and 'urgent care' instructions unless quoted from label). Add omitted label-critical elements (contraindications and boxed warning content if being summarized). When discussing drug interactions, align terminology with label phrasing (e.g., 'respiratory depression' rather than 'breathing suppression').